HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Avelumab maintenance extends OS in advanced urothelial carcinoma Mark Leiser
-
- ADT and COVID-19 — A therapeutic discussion Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Children with cancer ‘at no higher risk’ for COVID-19 infection, morbidity Jennifer R. Southall
- Recommendations seek ‘similarity across trials’ of therapies for sickle cell disease Jennifer Byrne
- NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research Mark Leiser
- Pembrolizumab plus axitinib prolongs survival in advanced renal cell carcinoma Mark Leiser
- Adjuvant dabrafenib-trametinib provides ‘real chance to cure’ BRAF-mutant melanoma Mark Leiser
- Anthracycline chemotherapy shows no benefit in HER2-positive breast cancer Jennifer R. Southall
- Auto-HSCT ‘still relevant’ for chemosensitive, relapsed diffuse large B-cell lymphoma Drew Amorosi
-
- Prior chemotherapy linked to mortality risk among patients with thoracic cancers, COVID-19 John DeRosier
- Longer-term imatinib treatment extends OS among patients with GIST Jennifer R. Southall
- Pembrolizumab doubles PFS for certain patients with metastatic colorectal cancer Mark Leiser
- Nivolumab plus ipilimumab confers sustained survival benefit in advanced NSCLC John DeRosier
- Mobility program benefits hospitalized patients with cancer Mark Leiser
- Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer John DeRosier
- Continuous dosing of BRAF and MEK inhibitors improves PFS in melanoma subset John DeRosier
- Suicide risk higher within 1 year of brain cancer diagnosis Jennifer R. Southall
-
- Novel agent appears safe, effective for relapsed, refractory diffuse large B-cell lymphoma Jennifer R. Southall
- Discontinuation of first-line dasatinib safe for certain adults with chronic myeloid leukemia Jennifer R. Southall
- Colon cancer relapse, death more common among children, young adults Jennifer R. Southall
- Compression stockings may be unnecessary to prevent VTE after elective surgery Jennifer R. Southall
- FDA approves four NSCLC regimens
- FDA approves Lynparza for prostate cancer subset
- NCCN Foundation presents young investigator awards
- Roswell Park Comprehensive Cancer Center makes three appointments
-